med-research工作流程:编写精确的 PubMed 检索式、解读标注、判断未标注论文的研究类型,并在报告研究发现时说明其确定程度。阅读 SKILL.md 收起
Use when researching biomedical, supplement, peptide, or longevity evidence with the med-research-mcp MCP server (tools literature_search, literature_fetch, literature_fulltext). Covers writing precise PubMed queries with field tags, reading study designs (studyType, 0-5 designTier, flags), classifying unlabeled papers from the abstract, the ground rules of weighing evidence, choosing between search/fetch/fulltext, multi-database searches, and how to report findings. Three few-shot patterns (lookup, synthesis, bullshit) show the exact workflow. Trigger on questions about what the research/evidence says for a compound, dose, intervention, or biomarker.
Using the med-research-mcp MCP
Three tools, a triage-first workflow. Always start with literature_search (free, designs labeled from NLM metadata), drill into papers with literature_fetch, and use literature_fulltext only when the abstract isn't enough.
Decision flow
- Turn the question into a query (below) and call
literature_search. Default database is"pubmed"; for broader coverage use["pubmed","europepmc"],["pubmed","chinaxiv"], or"all". For a preprint or a paper outside MEDLINE search"europepmc"alone (SRC:PPRkeeps preprints only; PubMed reads it as words and has the NIH-supported ones)."russiarxiv"is Soviet-era papers, mostly mathematics, physics and chemistry, almost no medicine: a zero there is not "no Russian research exists". - Read
warningsandflagsfirst. Then read the abstract of every result whosedesignTierisnull: unclassified records and most meta-analyses/systematic reviews. Null means unrated, not weak. literature_fetchthe ids you care about (with theirdatabase) to read whole abstracts.literature_fulltextonly when the abstract isn't enough: dosage, sample sizes, methods, statistical flaws.- Europe PMC records indexed in MEDLINE carry the same NLM labels as PubMed. Its preprints (
PPR…) andCBA:…records have no design tag, so they areunknown, like all ChinaXiv/RussiaRxiv records — you classify them. ChinaXiv/RussiaRxiv come through ChinaRxiv, a third-party service; ChinaXiv records are preprints.
Writing good queries (literature_search)
2–5 keywords, never a sentence: every word must match, so each extra word narrows the result. On 0 results the warning names the word that blocks a query of plain words (no quotes, tags or operators), or says no single word does (use fewer, more general words); with tags, drop one clause at a time. PubMed ignored "word" means no record contains it: check the spelling. PubMed has no phrase "…" means PubMed found no such phrase and searched its words separately, anywhere in a record. Tags and booleans add precision on PubMed and Europe PMC; chinaxiv/russiarxiv ignore them.
[tiab]— title/abstract (most precise):zinc[tiab] AND ("common cold"[tiab] OR rhinovirus[tiab]). Quote a phrase before its tag or tag each word: Europe PMC drops the tag ofcommon cold[tiab].[mesh]— controlled MeSH, PubMed only:"Zinc"[mesh] AND "Common Cold"[mesh][au]— author:Hemilä H[au][pt]— publication type, for strong designs:AND (meta-analysis[pt] OR "randomized controlled trial"[pt])- Europe PMC reads
[tiab] [ti] [au] [pt] [ta] [la] [dp] [pmid]and drops other tags, so their words match full text. chinaxiv/russiarxivreturn only records containing every word, and readORas a word: give them one or two key words.
Params (the tool descriptions have the rest):
maxResults(default 10, max 50) counts per database and page: two databases return up to 20.abstractMaxCharscuts abstracts to that many characters (0 leaves them out). Ten whole abstracts run 20,000–30,000 characters: with several databases or many results set one (600 halves it).abstractTruncated: true(also on ChinaXiv/RussiaRxiv previews, cut at 500 characters) meansliterature_fetchthe record for the whole abstract.page: pass a result'snextPagewith the samemaxResultsto read on. Each page is sorted on its own.studyTypes(e.g.["meta-analysis","systematic-review","randomized-controlled-trial"]): use this to keep reviews and trials.cohort,case-control,cross-sectionalandin-vitronever match.minDesignTier(4 = RCTs): drops everynulltier, including most meta-analyses; read the warning.
Reading the design labels (GradedArticle)
studyType comes only from NLM PublicationType tags — no text guessing. NLM now assigns them by automated indexing, with human review of only some records, so treat them as a strong prior: confirm in the abstract when it matters. † marks what only you assign, from the abstract: the tool never returns tier 3, gives 5 only to a Network Meta-Analysis tag, and never names cohort, case-control, cross-sectional or in-vitro (tagged observational studies come back as observational). designTier ranks the design for "does this intervention help?" by the OCEBM 2011 levels [1] — a prior, not an appraisal.
| designTier | studyType | Reading |
|---|---|---|
| 5 | meta-analysis / systematic-review of randomized trials † | most reliable design for treatment effects; a review of weak trials is still weak |
| 4 | randomized-controlled-trial | randomized comparison. NLM also tags secondary/post-hoc analyses of trials this way — check that the comparison you cite is the randomized one |
| 3 | cohort † | observational with a comparison group; confounding likely |
| 2 | non-randomized-trial · clinical-trial · observational · case-control † · cross-sectional † | controlled but not randomized (historical controls possible) · a trial whose randomization and control aren't indexed (may be single-arm) · an observational study of unindexed design · hypothesis-generating designs |
| 1 | case-report · review | anecdote · review article not indexed as systematic (16% of 2023 papers titled "systematic review" carry only this tag — check) |
| 0 | animal-study · in-vitro †, or any record flagged retracted / notice / protocol / editorial | not usable as evidence for human benefit |
null | meta-analysis / systematic-review | what it pooled isn't in the metadata — read the abstract: of RCTs → tier 5; of observational studies → the tier of those studies |
null | unknown | no design metadata, not weak — recent, non-MEDLINE or regional record; classify it yourself |
flags — tier 0: retracted (never cite as support), notice (a retraction notice, expression of concern or erratum, not a study), protocol (planned study, no results), editorial (opinion or commentary). Warnings, tier unchanged: expression-of-concern (the journal doubts its integrity; don't rely on it alone), corrected (an erratum exists — check the numbers you quote), updated (a newer version exists: an updated Cochrane review, or a preprint's published article, whose id is in corrections — cite that one, fetching it if needed), animals-not-humans (MeSH lists animals but not humans; usually an animal study, but automated indexing sometimes drops the Humans tag from real human trials [9] — check the abstract), preprint (not peer reviewed), letter (may be correspondence or a short research report), machine-translated (ChinaXiv/RussiaRxiv text is a machine translation — confirm numbers in originalUrl), machine-generated-abstract (the abstract is ChinaRxiv's summary, not the authors' — never quote it as the paper's findings). Dosage, population, sample size and limitations are not extracted — read them in the abstract.
Classifying from the abstract
Use the same labels. Do it for unknown results, and refine clinical-trial, observational and unrated syntheses. Classify the paper's own design, not designs it mentions ("previous RCTs showed…", "further trials are needed" describe other work). Reporting guidelines ask authors to name the design in the title or abstract [10].
- Pooled studies found by a stated search →
meta-analysis(pooled numerically) /systematic-review, and note what designs it pooled. An unsystematic overview →review. - Investigators assigned the intervention: randomly →
randomized-controlled-trial; with a non-random control group →non-randomized-trial; single-arm →clinical-trial(rank it like a case series). - Observed only: groups compared over time →
cohort; cases compared with controls →case-control; one time point or a survey →cross-sectional; one or a few patients →case-report. - Animals or cells only, no human participants →
animal-study/in-vitro, even if randomized. - Future tense ("we will randomize"), "protocol" → a protocol, not results. Unsure between two designs → take the lower one.
Say when a design is your reading of the abstract, not a database label.
Ground rules of evidence
Apply these to every answer, not only pivotal ones.
- Design is the starting point, not the verdict. Certainty drops for risk of bias, imprecision, inconsistency, indirectness and publication bias [2], and can rise for a large effect [1] or a dose–response gradient [3].
- The best design depends on the question. Treatment benefit: randomized trials. Harms: randomized trials too, but rare or long-term harms often show only in large observational follow-up (post-marketing surveillance). Prognosis: inception cohorts. Diagnostic accuracy: cross-sectional studies against a reference standard [1]. The tier assumes a treatment-benefit question.
- Association is not causation. Observational studies show associations that confounding or reverse causation can explain. Weigh causal claims with the Bradford Hill considerations, none of which settles causation on its own [3]; a cause must precede its effect, so always check temporality.
- Absence of evidence is not evidence of absence. No trial found, or a non-significant result with a wide confidence interval, means "unknown", not "doesn't work" [4].
- Weigh all the evidence, not the study that agrees. Search for null and negative results too, and prefer systematic reviews. Small, single, surprising or implausible positive findings are often false [5].
- Effect size and relevance over p-values. Report absolute effects with confidence intervals; a statistically significant change can be clinically irrelevant [1].
- Improvement without a control group proves little. Regression to the mean [6] and placebo effects, which can influence patient-reported outcomes such as pain and nausea [7], make before–after studies and single-arm trials look effective.
- Directness. The population, intervention and dose, comparator and outcome must match the question; surrogate outcomes and animal data are indirect [8].
- Newer, larger trials can overturn earlier evidence. Large RCTs agreed only fairly with earlier meta-analyses (κ = 0.35) [11], and 40% of established practices tested in one major journal over 10 years were reversed [12]. Check dates; prefer the latest systematic review.
- State certainty honestly. Use GRADE's levels [2] and matching wording: "results in" (high), "likely results in" (moderate), "may result in" (low) [13]; for very low certainty say the evidence is very uncertain.
Tools, limits, errors
literature_fetch({ids:["39123456","38987654"], database:"pubmed"})— 1–50 ids of one database (a result'sidanddatabase): whole abstracts, publication types, MeSH, retraction/correction links, and the samestudyType/designTier/flagsas search.literature_fulltext({id:"39123456"})— article body as markdown via Europe PMC (records with apmcid) → Unpaywall → proxy → DOI; otherwise the abstract, andwarningsays why. A result'sidworks alone, with its prefix (CBA:644599; a bare number is a PMID);doiis only for an id Europe PMC doesn't know; aurlis not a DOI.warningopens withRETRACTED:,NOTICE:orEXPRESSION OF CONCERN:when the record has that flag, even if the text came (say so first); it reads the record as the databases report it at the time, so the flags of search or fetch are the authority. A long text comes in parts: whiletruncatedis true, call again withoffset: nextOffset.- NCBI is rate-limited: parallel calls are safe but don't run faster. Prefer a few precise queries.
- Errors:
QUERY_TOO_BROAD(narrow: add a[tiab]term or anANDclause);RATE_LIMIT(the server already retried; waitretryAfter);NETWORK_ERROR/PARSE_FAILURE(retry once, then say the DB is unreachable);TIMEOUT(retry, then ask for an earlier page or narrow the query);INVALID_INPUTand schema errors (fix the parameter named: database ids are lower case, dates must exist). In a multi-database search, a database that fails while others answer shows up only inwarnings(<database> search failed: …): say which is missing, never report it as "no studies found".
Reporting
Lead with the strongest evidence, its design and how certain it is; summarize consensus, then contradictions. If a record you rely on is flagged retracted, notice or protocol, the answer's first sentence says so. Cite the id the tool returned, as "PMID …" only when the record has pmid, otherwise with its database (PPR…, chinaxiv-…) or the doi/url; never type an id from memory. Report doses and populations as what the studies used and found, quoted from the abstract or the full text you read (say which), not as recommendations, and call out animal-only, tiny or abstract-less results. Surface the other flags (expression of concern, updated, preprint, machine-translated) and what you read yourself (COI, n<20). This is a research summary, not medical advice: say so when the question is about dosing or treatment, and point to a healthcare professional for decisions about a person's care.
Three patterns (follow these, don't ad-lib)
1. Simple lookup — known PMID
"What study design is PMID 22570464, and how strong is that design?"
One call, no fan-out: literature_search({query:"22570464[pmid]"}) — it returns studyType, designTier, flags and the abstract. If flags has retracted/notice/protocol, say so first. If designTier is null, read the abstract: for a synthesis, find what it pooled; for unknown, classify it (above) and say so. Answer: "Systematic review and meta-analysis of randomized controlled trials — 82 met the inclusion criteria, 63 were pooled (NLM tag; pooled designs from the abstract): design tier 5 of 5 (PMID 22570464)." Stop.
2. Evidence synthesis — compare X vs Y
"Compare intranasal corticosteroids vs oral antihistamines for allergic rhinitis symptoms. Which has stronger evidence, and why?"
Frame PICO, then two targeted searches (one per arm, study-type filter): "intranasal corticosteroid*"[tiab] AND "allergic rhinitis"[tiab] AND (meta-analysis[pt] OR "randomized controlled trial"[pt]), and "oral antihistamine*"[tiab] AND "allergic rhinitis"[tiab] AND (...). literature_fetch the top 2–3 ids per arm; read what each review pooled, effect sizes + CIs, n, I². Judge which arm's evidence is more certain, not which effect is bigger: start from design (a meta-analysis of RCTs beats one small RCT), then rate down as in ground rule 1. Name which arm is stronger and why; cite ids; state certainty in GRADE terms. Cap at ~6 calls.
3. Bullshit detection — the study doesn't exist
"Summarize the 2020 Nilsen trial on taurine and slow-wave sleep."
Search author+topic, then title terms, then both databases: Nilsen[au] AND taurine AND sleep; taurine slow-wave sleep 2020; taurine slow-wave sleep Nilsen with database: ["pubmed","europepmc"]. Nothing corroborating after these three queries → STOP — don't keep reformulating 8–10 times and return empty. Answer plainly, naming the databases searched (databases in the result): "I could not find this trial in PubMed or Europe PMC; it does not appear to exist." Invent no id, cite no fabricated study. Suggest the user double-check the reference.
Small-model tips
- Budget your calls: 1 for a lookup, ~4–6 for synthesis, three queries (pattern 3) before you say nothing was found. Then stop and say so: never return an empty answer; a caveat beats silence.
- Lead with the bottom line: the winner or number first, then design, certainty, citation, flags.
When to go deeper (EBM)
The 0–5 design tier orients you; it does not appraise a study. When a conclusion will rest on one paper and you need risk-of-bias (RoB 2 / ROBINS-I), AMSTAR 2, effect sizes/CIs/NNT, heterogeneity, Bradford Hill causation, or applicability checks, load the med-research-ebm reference skill. Don't load it for routine searches — it's heavy.
References
- OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence, and its Introductory Document. Oxford Centre for Evidence-Based Medicine. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
- Balshem H, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. PMID 21208779
- Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300. PMID 14283879
- Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485. PMID 7647644
- Ioannidis JPA. Why most published research findings are false. PLoS Med 2005;2:e124. PMID 16060722
- Barnett AG, et al. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005;34:215-20. PMID 15333621
- Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010;CD003974. PMID 20091554
- Guyatt GH, et al. GRADE guidelines: 8. Rating the quality of evidence — indirectness. J Clin Epidemiol 2011;64:1303-10. PMID 21802903
- Askin N, et al. Filtering failure: the impact of automated indexing in Medline on retrieval of human studies for knowledge synthesis. J Med Libr Assoc 2025. PMID 39975499
- Hopewell S, et al. CONSORT 2025 statement. BMJ 2025;389:e081123 (PMID 40228833), item 1a; Vandenbroucke JP, et al. STROBE: explanation and elaboration. PLoS Med 2007;4:e297 (PMID 17941715), item 1a; Page MJ, et al. The PRISMA 2020 statement. BMJ 2021;372:n71 (PMID 33782057), item 1
- LeLorier J, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42. PMID 9262498
- Prasad V, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 2013;88:790-8. PMID 23871230
- Santesso N, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 2020;119:126-135. PMID 31711912
